RESUMEN
BACKGROUND: Use of chimeric antigen receptor (CAR) T cells has become a promising strategy in cancer immunotherapy. However, safety in clinical application is also one of the most controversial issues. METHODS: In the present study, we investigated the application of a non-viral site-directed vector (CELiD [closed-ended linear duplex DNA]) dependent on adeno-associated virus (AAV) genomes for the purpose of safe CAR-T engineering. We co-electroporated CD19-CAR encoding "CELiD" vectors with plasmid pCMV-Rep into human T cells and ensured stably transfected CAR-T cells by G418 selection. The efficiency of AAVS1 site-specific integration was analyzed by a real-time polymerase chain reaction. RESULTS: CAR-T cells engineered by CELiD vectors could be established within 20 days with up to 22.8% AAVS1 site-specific integration efficiency. CAR expression and cytokine secretion of CAR modified T cells were evaluated in vitro. Abundant effector cytokines were produced by the CAR-T cells engineered by CELiD vectors compared to control T cells and the killing efficiency of target cells was estimated to as high as 75% in vitro. CONCLUSIONS: With the help of the AAV-derived CELiD vector, CAR genes were preferentially integrated into the AAVS1 site. This technology could be utilized in human T cell modification and remove the safety constraints of CAR-T therapy.
Asunto(s)
Dependovirus/genética , Vectores Genéticos/genética , Receptores Quiméricos de Antígenos/genética , Linfocitos T/metabolismo , Transducción Genética , Transgenes , Integración Viral , Antígenos CD19/genética , Antígenos de Neoplasias/genética , Antígenos de Neoplasias/inmunología , Línea Celular , Citotoxicidad Inmunológica , Expresión Génica , Orden Génico , Ingeniería Genética , Humanos , Inmunofenotipificación , Receptores Quiméricos de Antígenos/inmunología , Linfocitos T/inmunologíaRESUMEN
Xanthine oxidase (XOD) is a key enzyme that catalyzes xanthine to uric acid. Most of the urate-lowering medicines targeting XOD have a limited effect on alleviating inflammation in spite of significant effects on decreasing serum uric acid level. In this study, we produced and characterized a novel monoclonal antibody (Anti-XOD mAb) using hybridoma technology based on a novel peptide OI5P-1(O-IA2(5)-P2-1),which containing a B-cell epitope of XOD and a novel Th2 built-in adjuvant I5P-1(IA2(5)-P2-1). Results of western blotting and cross-reactivity assay indicated that the mAb binds specifically to XOD and the affinity was 2.523×1010L/mol. The mAb reduced serum uric acid level and hepatic xanthine oxidase activity in potassium oxonate induced mice. A decreased methane dicarboxylic aldehyde level and an improved superoxide dismutase level in mAb treated mice indicated anti-lipid peroxidation effects of the mAb. Moreover, the mAb showed a significant immunomodulatory effect which could shift Th1/Th2 balance to Th2-dominant immunity. The mAb treatment alleviates inflammation induced by potassium oxonate, superior to the small molecule allopurinol treatment. For the first time, these results showed that the anti-XOD mAb may serve as a promising therapeutic approach for inflammatory response related to uric acid.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Inmunoglobulina G/uso terapéutico , Inflamación/tratamiento farmacológico , Xantina Oxidasa/antagonistas & inhibidores , Alopurinol/farmacología , Animales , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/aislamiento & purificación , Anticuerpos Monoclonales/farmacología , Afinidad de Anticuerpos/efectos de los fármacos , Antioxidantes/metabolismo , Creatinina/sangre , Reacciones Cruzadas/inmunología , Femenino , Sueros Inmunes , Inmunización , Inmunoglobulina G/farmacología , Inflamación/sangre , Inflamación/patología , Riñón/efectos de los fármacos , Hígado/enzimología , Malondialdehído/sangre , Ratones , Ratones Endogámicos BALB C , Ácido Oxónico , Sustancias Protectoras/farmacología , Bazo/patología , Superóxido Dismutasa/sangre , Células TH1/efectos de los fármacos , Células TH1/inmunología , Células Th2/efectos de los fármacos , Células Th2/inmunología , Urea/sangre , Ácido Úrico/sangre , Xantina Oxidasa/metabolismoRESUMEN
Type 1 diabetes is a chronic organ-specific autoimmune disease in which selective destruction of insulin-producing ß cells leads to impaired glucose metabolism and its attendant complications. IA2(5)P2-1, a potent immunogenic carrier which designed by our laboratory, can induce high titer specific antibodies when carry a B cell epitope, such as B cell epitopes of DPP4, xanthine oxidase, and Urate transporter protein. In this report, we describe a novel multi-epitope vaccine composing a peptide of DPP4, an anti-diabetic B epitope of Insulinoma antigen-2(IA-2) and a Th2 epitope (P2:IPALDSLTPANED) of P277 peptide in human heat shock protein 60 (HSP60). Immunization with the multi-epitope vaccine in non-obese diabetic (NOD) mice successfully induced specific anti-DPP4 antibody, inhibited plasma DPP4 activity, and increased serum GLP-1 level. Moreover, this antibody titer was correlated with the dose of immunization (20µg, 100µg). Inoculation of this vaccine in NOD mice significantly control blood glucose level, improved glucose excursion and increased insulin level in vivo. Consistent with a lower diabetic and insulitis incidence, a induced splenic T cells proliferation and tolerance were observed. IFN-γ secretion reduced and IL-10 increased significantly in the D41-IA2(5)-P2-1 treated mice compared to P277 and control group due to the potential immunomodulatory effect of the epitope in the vaccine. Immunohistochemical analysis and cytometry showed a rebalance of Th1/Th2 in NOD mice. Our results demonstrate that this multi-epitope vaccine may serve as a promising therapeutic approach for type 1 diabetes.
Asunto(s)
Diabetes Mellitus Tipo 1/terapia , Dipeptidil Peptidasa 4/inmunología , Epítopos de Linfocito B/inmunología , Proteínas Tirosina Fosfatasas Clase 8 Similares a Receptores/inmunología , Vacunas de Subunidad/inmunología , Vacunas/uso terapéutico , Animales , Formación de Anticuerpos , Glucemia/análisis , Chaperonina 60/inmunología , Citocinas/biosíntesis , Citocinas/inmunología , Diabetes Mellitus Tipo 1/inmunología , Dipeptidil Peptidasa 4/sangre , Dipeptidil Peptidasa 4/química , Epítopos de Linfocito B/química , Epítopos de Linfocito B/genética , Péptido 1 Similar al Glucagón/sangre , Humanos , Insulina/sangre , Ratones , Ratones Endogámicos NOD , Proteínas Tirosina Fosfatasas Clase 8 Similares a Receptores/genética , Linfocitos T/inmunología , Vacunas/administración & dosificación , Vacunas/inmunología , Vacunas de Subunidad/administración & dosificación , Vacunas de Subunidad/químicaRESUMEN
Hyperuricemia (HUA) is related to diabetes. Uric acid-induced inflammation and oxidative stress are risk factors for diabetes and its complications. Human urate transporter 1 (URAT1) regulates the renal tubular reabsorption of uric acid. IA-2(5)-P2-1, a potent immunogenic carrier designed by our laboratory, can induce high-titer specific antibodies when it carries a B cell epitope, such as B cell epitopes of DPP4 (Dipeptidyl peptidase-4), xanthine oxidase. In this report, we describe a novel multi-epitope vaccine composing a peptide of URAT1, an anti-diabetic B epitope of insulinoma antigen-2(IA-2) and a Th2 epitope (P2:IPALDSLTPANED) of P277 peptide in human heat shock protein 60 (HSP60). Immunization with the multi-epitope vaccine in streptozotocin-induced diabetes C57BL/6J mice successfully induced specific anti-URAT1 antibody, which inhibited URAT1 action and uric acid reabsorption, and increased pancreatic insulin level with a lower insulitis incidence. Vaccination with U-IA-2(5)-P2-1 (UIP-1) significantly reduced blood glucose and uric acid level, increased Th2 cytokines interleukin (IL)-10 and IL-4, and regulated immune reactions through a balanced Th1/Th2 ratio. These results demonstrate that the URAT1-based multi-epitope peptide vaccine may be a suitable therapeutic approach for diabetes and its complications.
Asunto(s)
Autoanticuerpos/inmunología , Autoantígenos/inmunología , Diabetes Mellitus Experimental/inmunología , Epítopos/inmunología , Inmunomodulación , Transportadores de Anión Orgánico/inmunología , Vacunas/inmunología , Animales , Antioxidantes/metabolismo , Citocinas/metabolismo , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Tipo 1/inmunología , Diabetes Mellitus Tipo 1/metabolismo , Diabetes Mellitus Tipo 1/patología , Glucosa/metabolismo , Hiperglucemia/metabolismo , Hiperuricemia/inmunología , Inmunoglobulina G/inmunología , Islotes Pancreáticos/inmunología , Islotes Pancreáticos/metabolismo , Islotes Pancreáticos/patología , Malondialdehído/metabolismo , Ratones , Superóxido Dismutasa/metabolismo , Linfocitos T/inmunología , Linfocitos T/metabolismo , Ácido Úrico/sangreRESUMEN
Type 1 diabetes is a chronic organ-specific autoimmune disease in which selective destruction of insulin-producing ß-cells leads to impaired glucose metabolism and its attendant complications. A series of Dipeptidyl peptidase 4 (DPP4) inhibitors have been developed and granted approval in the treatment of type 2 diabetes mellitus by inhibiting the enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). An increasing number of studies have shown the potential benefits of DPP4 inhibitors for type 1 diabetes. In this report, we describe a novel multi-epitope vaccine comprising a B cell epitope of DPP4, an anti-diabetic B cell epitope of Insulinoma antigen-2 (IA-2) and a Th2 epitope of P277 peptide in human heat shock protein 60 (HSP60). Immunization with the multi-epitope vaccine in streptozotocin (STZ) treated mice successfully induced specific anti-DPP4 antibody and increased serum GLP-1 level. Moreover, this antibody lasted for more than 7 weeks. Inoculation of this vaccine in C57BL/6J mice significantly reduced blood glucose level, improved glucose excursion and increased plasma insulin concentration. Consistent with a lower diabetic and insulitis incidence, induced splenic T cell proliferation and tolerance were observed. IFN-γ and IL-2 secretion reduced, but IL-10 and IL-4 increased significantly in the Dipeptidyl Peptidase 41-Insulinoma antigen-2(5)-P2-1 (D41-IP) treated mice compared to the Insulinoma antigen-2(5)-P2-1 (IA2(5)P2-1) and control group due to the potential immunomodulatory effect of the epitopes in the vaccine. Our results demonstrate that this multi-epitope vaccine may serve as a promising therapeutic approach against type 1 diabetes.
Asunto(s)
Diabetes Mellitus Experimental/inmunología , Diabetes Mellitus Tipo 1/inmunología , Dipeptidil Peptidasa 4/inmunología , Inhibidores de la Dipeptidil-Peptidasa IV/farmacología , Epítopos/inmunología , Factores Inmunológicos/inmunología , Vacunas/inmunología , Animales , Linfocitos B/efectos de los fármacos , Linfocitos B/inmunología , Glucemia/efectos de los fármacos , Glucemia/inmunología , Proliferación Celular/efectos de los fármacos , Chaperonina 60/metabolismo , Diabetes Mellitus Experimental/inducido químicamente , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Tipo 1/inducido químicamente , Diabetes Mellitus Tipo 1/metabolismo , Péptido 1 Similar al Glucagón/metabolismo , Glucosa/metabolismo , Humanos , Insulina/sangre , Interleucinas/inmunología , Masculino , Ratones , Ratones Endogámicos C57BL , Estreptozocina/farmacología , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunologíaRESUMEN
Tumor-derived autophagome (DRibble) is an effective therapeutic cancer vaccine inducing T cell recognition and death of tumor cells in mice. However, the potential for improved anti-tumor response still remains. Our previous study demonstrated that two repeats of a mycobacterial HSP70407-426 (M2) peptide acted as adjuvant in improving anti-tumor efficacy of human umbilical vein endothelial cell (HUVEC) vaccine. Here, a DRibble vaccine conjugated with M2 (DRibble-M2) was designed as a novel vaccine to enhance anti-tumor activity. Compared with DRibble alone, DRibble-M2 vaccination more significantly inhibited the growth of mouse Lewis lung cancer both in a subcutaneous tumor model and in a lung metastasis model. Higher expression of antigen-specific CTL was induced by DRibble-M2. DRibble-M2 induced higher CD83 and CD86 expression in DC2.4 and also improved the internalization of DRibble antigen into DC2.4. Our data indicated that DRibble-M2 is a potential vaccine for clinical cancer therapy.
Asunto(s)
Autofagosomas/inmunología , Vacunas contra el Cáncer/inmunología , Carcinoma Pulmonar de Lewis/terapia , Epítopos/inmunología , Proteínas HSP70 de Choque Térmico/inmunología , Inmunoterapia Activa , Fragmentos de Péptidos/inmunología , Adyuvantes Inmunológicos , Animales , Apoptosis , Vacunas contra el Cáncer/administración & dosificación , Carcinoma Pulmonar de Lewis/inmunología , Carcinoma Pulmonar de Lewis/patología , Proliferación Celular , Células Cultivadas , Células Dendríticas/inmunología , Citometría de Flujo , Células Endoteliales de la Vena Umbilical Humana/inmunología , Humanos , Inmunoterapia Adoptiva , Masculino , Ratones , Ratones Endogámicos C57BL , Linfocitos T Citotóxicos/inmunologíaRESUMEN
The cytotoxic T-lymphocyte antigen 4 (CTLA-4) polymorphic loci -318 cytosine/thymine (-318C/T) has been previously implicated in malignant tumor susceptibility. However, there were no precise conclusions about the correlation, the results from published studies were inconclusive. The aim of the current meta-analysis was to investigate the associations between CTLA-4 -318C/T polymorphisms and risk of malignant tumors in Asian population. We conducted a search in PubMed, Embase, the Chinese Journals Full-Text Database, Chinese Biomedical Database, and the Wanfang database. All studies were published up to September 30, 2015. Two reviewers analysed the data independently. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the association. In total, 20 case-controlled studies with 3,539 cases and 4,690 controls were included in the final meta-analysis. The overall estimation demonstrated a significant association between CTLA-4 -318C/T polymorphism and malignant tumor risk in the Asian populations (TT+TC vs. CC: OR, 1.28; 95% CI, 1.07-1.53. TT vs. TC+CC: OR, 1.43; 95% CI, 1.03-1.99; TT vs. CC: OR, 1.51; 95% CI, 1.09-2.10. TC vs. CC: OR, 1.26; 95% CI, 1.06-1.50. T vs. C: OR, 1.25, 95% CI, 1.05-1.47). In the subgroup analysis by countries, we found that the dominant model (TT+TC vs. CC) revealed an increased risk of developing malignant tumors in the Chinese study population (OR, 1.41; 95% CI, 1.13-1.76), but no association was demonstrated in the other countries. The current meta-analysis suggests that CTLA-4 -318C/T polymorphism is significantly associated with the risk of malignance tumors in Asian populations, especially in those from China. Further studies for additional Asian countries are required to further evaluate the association.
RESUMEN
OBJECTIVE: To investigate the effects of Tetrandrine (TET) prenatal intervention on the differentiation of alveolar epithelial cells type I (AEC I) in rat model of Nitrofen-induced congenital diaphragmatic hernia (CDH). METHODS: Timed-pregnant Sprague-Dawley rats were divided into three groups, namely control, CDH and TET group on day 9.5 of gestation. The rats in TET group and CDH group were given 125 mg of Nitrofen by gavage one time, while the rats in control group were given the same dose of seed fat. After that, the rats in TET group was given 30 mg/kg of TET by gavage once a day for three days from day 18.5 of gestation, while the rats in CDH and control group were given the same dose of normal saline. On day 21.5 of gestation, all fetuses were delivered by cesarean, the lungs of fetuses were histologically evaluated by microscope and electron microscope. The expressions of type I cell-specific protein (RT140) and thyroid transcription factor 1 (TTF1) in alveolar fluid content were analyzed by RT-PCR and immunohistochemistry staining. To detect the number of AEC I and AEC II of each group by transmission electron microscopy and calculate the percentage of AEC I and AEC II (I/II%). RESULTS: The microscope and electron microscope study found the lungs of fetuses in CDH group showed marked hypoplasia, in contrast to the improvement of hypoplasia in TET fetuses. The pulmonary alveolar area had significant difference statistically (P < 0.01) in each group, which present as control > TET > CDH. I/II% had significant difference statistically (P < 0.01) in each group, which present as control > TET > CDH. The expression level of TTF1 was up-regulated in both CDH and TET groups, and it was higher in CDH group (P < 0.01). The expression level of RT140 were down-regulated in CDH and TET groups, which was lower in CDH group (P < 0.01). CONCLUSION: The development of AEC I was interfered in CDH rat model, TET prenatal treatment could improve the lung development of CDH.
Asunto(s)
Células Epiteliales Alveolares/citología , Bencilisoquinolinas/farmacología , Diferenciación Celular/efectos de los fármacos , Hernias Diafragmáticas Congénitas/tratamiento farmacológico , Animales , Modelos Animales de Enfermedad , Femenino , Feto , Hernias Diafragmáticas Congénitas/inducido químicamente , Inmunohistoquímica , Pulmón/crecimiento & desarrollo , Pulmón/patología , Éteres Fenílicos/efectos adversos , Embarazo , Ratas , Ratas Sprague-DawleyRESUMEN
Exosomes, a population of extracellular membrane vesicles of 30-100 nm in diameter, play important roles in cell biological functions, intercellular signal transduction and especially in cancer diagnosis and therapy. To better apply exosomes in mechanistic study of breast cancer signal transduction, we constructed recombinant eukaryotic expression vector expressing the near-infrared fluorescence protein and CD63 fusion protein through cloning iRFP682 gene and exosomal marker protein CD63 gene into plasmid containing the ITR of AAV. The constructed plasmids were co-transfected with helper plasmid in AAV-293 cell lines and were packaged into rAAV. After titer measurement, the recombinant plasmids were transfected into breast cancer cell lines. The cell lines that stably expressing near-infrared fluorescence protein were selected by fluorescence. Through isolation, purification and identification, we finally obtained a new biomarker: iRFP682 labeled exosomes secreted by breast cancer cell lines, which could be used in further studies of the distribution and signal transduction of exosomes in breast cancer microenvironment.
Asunto(s)
Neoplasias de la Mama/ultraestructura , Exosomas , Línea Celular Tumoral , Dependovirus/genética , Femenino , Colorantes Fluorescentes , Humanos , Plásmidos , Proteínas Recombinantes de Fusión/genética , Tetraspanina 30/genéticaRESUMEN
Previous evidence has proved the ability of immunization with heat shock protein (HSP) 60/65 to induce atherosclerosis. P277, a 24-residue peptide of human HSP60, is a promising peptide vaccine against autoimmune diabetes. But as a fragment of HSP60, its potential ability of promoting atherosclerosis has never been investigated yet. In the present study, the rabbits fed with normal standard diet or high cholesterol diet were immunized with P277 or PBS emulsified in incomplete Freund's adjuvant 4 times at 4-week intervals. Atherosclerotic lesions of the rabbits receiving P277 treatment and fed with high cholesterol diet increased significantly compared with those of the rabbits receiving PBS treatment and the same diet. However, no obvious lesions were found in the two groups of rabbits fed with the normal standard diet. Significant expression of P277 was detected in the high cholesterol diet-induced atherosclerotic lesions and heat-stressed endothelial cells. Surface exposure of P277 was also observed in the stressed cells. In the subsequent assay of endothelial cells in vitro, the purified anti-P277 antibodies mediated a noticeable cytotoxicity to the stressed cells with the participation of complement. In conclusion, subcutaneous immunization with P277 emulsified in IFA can aggravate the atherosclerosis in high cholesterol diet-fed rabbits. Surface expression of P277 was observed on stressed endothelial cells, and were suggested to mediate the autoimmune attack and promote the disease.
Asunto(s)
Aterosclerosis/etiología , Chaperonina 60/inmunología , Colesterol , Dieta Alta en Grasa , Inmunización , Fragmentos de Péptidos/inmunología , Animales , Anticuerpos/sangre , Anticuerpos/inmunología , Aorta/metabolismo , Aorta/patología , Aterosclerosis/patología , Membrana Celular/metabolismo , Chaperonina 60/metabolismo , Chaperonina 60/farmacología , Colesterol/sangre , Células Endoteliales/efectos de los fármacos , Células Endoteliales/metabolismo , Epítopos/inmunología , Inmunohistoquímica , Masculino , Fragmentos de Péptidos/metabolismo , Fragmentos de Péptidos/farmacología , Conejos , Estrés FisiológicoRESUMEN
BACKGROUND: Macrophage migration inhibitory factor (MIF) -173G/C (rs755622) gene polymorphism has been associated with cancer risk. Previous studies have revealed that MIF -173G/C gene polymorphism may increase cancer in the Chinese population, while results of individual published studies remain inconsistent and inconclusive.We performed this meta-analysis to derive a more precise estimation of the relationship. MATERIALS AND METHODS: We conducted a search on PubMed, Embase, MEDLINE, Cochrane Library ,Chinese National Knowledge Infrastructure (CNKI), Wanfang, Weipu on Dec 31, 2014.Odds ratio (OR) and 95% confidence interval (95% CI) were used to assess the association. A total of eight studies including 2,186 cases and 2,285 controls were involved in this meta-analysis. RESULTS: The pooled results indicated the significant association between MIF -173G/C polymorphism and the risk of cancer for Chinese population (CC + CG vs GG: OR=1.14, 95%CI=1.02-127, pheterogeneity<0.01; P =0.023; CC vs CG+GG: OR=1.12, 95%CI=1.02- 1.23, pheterogeneity< 001; P =0.017;CC vs GG: OR=1.18, 95%CI=1.04-1.33, pheterogeneity<001; P =0.008; CG vs GG:OR=1.03, 95%CI=0.91-1.15, pheterogeneity<001; P =0.656; C vs G:OR=1.24, 95%CI=1.14-1.25, pheterogeneity<001; P <001). Subgroup analysis showed that in patients with "solid tumors", heterogeneity was very large (OR=0.94,95%CI=0.83-1.06,pheterogeneity=0.044; p=0.297). Within "non-solid tumors", the association became even stronger (OR=6.62, 95 % CI=4.32-10.14, pheterogeneity<0.001; p <0.001). CONCLUSIONS: This study suggested that MIF ?173G/C gene polymorphism may increase increase cancer in the Chinese population.Furthermore, more larger sample and representative population-based casees and well-matched controls are needed to validate our results.
Asunto(s)
Predisposición Genética a la Enfermedad , Oxidorreductasas Intramoleculares/genética , Factores Inhibidores de la Migración de Macrófagos/genética , Neoplasias/epidemiología , Neoplasias/genética , Polimorfismo Genético/genética , Estudios de Casos y Controles , China/epidemiología , Humanos , Metaanálisis como Asunto , Pronóstico , Factores de RiesgoRESUMEN
OBJECTIVE: To compare the protein expression differences between U937 macrophages expressing M. tuberculosis (MTB) Hsp16.3 protein and U937 macrophages expressing green fluorescent protein (GFP), and therefore to explore the protein expressions related to latent TB infection(LTBI). METHODS: U937 macrophages were infected with an integrase-deficient Lentivirus vector to transiently express MTB Hsp16.3, and green fluorescent protein (GFP) as a control. 2-DE was used to compare the differentially expressed proteins in the infected U937 cells. Then 5 significantly different expressed protein spots were identified by using mass spectrometry. RESULTS: The data of 6 protein spots in gel obtained from peptide mass fingerprinting were retrieved in protein database. They were identified as heat shock protein 70, actin, elongation factor I, peptidyl-prolyl cis-trans isomerase, ubiquitin-conjugation enzyme E2, and milk acyl glutathione lyase. CONCLUSION: The results showed that MTB specific protein intrusion resulted in changes of macrophage proteome expression, and this finding may help in understanding of the interaction between macrophages and MTB specific proteins.
Asunto(s)
Proteínas Bacterianas/metabolismo , Proteínas de Choque Térmico/metabolismo , Mycobacterium tuberculosis/metabolismo , Proteómica , Humanos , Macrófagos , Proteoma , Tuberculosis , Células U937RESUMEN
The plasmid vectors currently used for nonviral gene transfer have the disadvantage of carrying a bacterial backbone and an antibiotic resistance gene, which may cause side effects. The adeno-associated virus (AAV) genome is a linear single-stranded DNA (ssDNA) molecule with palindromic inverted terminal repeat (ITR) sequences forming double-stranded DNA (dsDNA) hairpin (HP) structures at each end. Based on the AAV genome, we constructed an AAV-ITR ssDNA minivector that consists of a GFP expression cassette flanked by both ITR sequences of 125 nucleotides. The minivectors were produced by digestion of the parental plasmids followed by denaturation. The self-complementary inverted T-shaped HP structure of the minivector was automatically formed. The HEK 293T cells were transfected with the AAV-ITR ssDNA minivector, plasmid, and dsDNA expression cassette. The results showed that AAV-ITR ssDNA minivector had relatively low gene expression efficiency in vitro. However, we found that the GFP expression efficiency of the D sequence-deleted AAV-ITR ssDNA minivector was significantly increased and was similar to those obtained with the plasmid and dsDNA expression cassette. Our data suggest that the AAV-ITR ssDNA minivector may be a new type of gene expression vector for gene therapy besides the virus and plasmid.
Asunto(s)
Clonación Molecular/métodos , ADN de Cadena Simple/genética , Dependovirus/genética , Plásmidos/genética , Secuencias Repetidas Terminales/genética , Expresión Génica , Proteínas Fluorescentes Verdes/química , Proteínas Fluorescentes Verdes/genética , Proteínas Fluorescentes Verdes/metabolismo , Células HEK293 , Humanos , TransfecciónRESUMEN
AAV-ITR gene expression mini vector is a double-strand or single-strand DNA that only contains inverted terminal repeats of adeno-associated virus, cis-elements and gene of interest and does not contain any other foreign DNA sequences. We prepared Bac-ITR-EGFP and Bac-inrep. Spodoptera frugiperda cells were infected with Bac-ITR-EGFP (P3) and Bac-inrep (P3). Up to 100 µg of AAV-ITR-EGFP gene expression mini vectors were extracted from 2 x 10(7) cells of Sf9 72 h after infection. The gel electrophoresis analysis shows that most forms of AAV-ITR-EGFP gene expression mini vector were monomer and dimer. The mini vector expression efficacy was examined in vitro with HEK 293T cells. The EGFP expression was observed at 24 h after transfection, and the positive ratio reached 65% at 48 h after transfection.
Asunto(s)
Baculoviridae , Dependovirus , Vectores Genéticos , Secuencias Repetidas Terminales , Animales , ADN de Cadena Simple , Expresión Génica , Células HEK293 , Humanos , Células Sf9 , TransfecciónRESUMEN
Diabetes mellitus type 1 (DM1) is an autoimmune disease that gradually destroys insulin-producing beta-cells. We have previously reported that mucosal administration of fusion protein of HSP65 with tandem repeats of P277 (HSP65-6P277) can reduce the onset of DM1 in non-obese diabetic (NOD) mice. To deliver large amounts of the fusion protein and to enhance long-term immune tolerance effects, in the present study, we investigated the efficacy of using orally administrated L. lactis expressing HSP65-6P277 to reduce the incidence of DM1 in NOD mice. L. lactis strain NZ9000 was engineered to express HSP65-6P277 either constitutively or by nisin induction. After immunization via gavage with the recombinant L. lactis strains to groups of 4-week old female NOD mice for 36 weeks, we observed that oral administration of recombinant L. Lactis resulted in the prevention of hyperglycemia, improved glucose tolerance and reduced insulitis. Immunologic analysis showed that treatment with recombinant L. lactis induced HSP65- and P277- specific T cell immuno-tolerance, as well as antigen-specific proliferation of splenocytes. The results revealed that the DM1-preventing function was in part caused by a reduction in the pro-inflammatory cytokine IFN-γ and an increase in the anti-inflammatory cytokine IL-10. Orally administered recombinant L. lactis delivering HSP65-6P277 may be an effective therapeutic approach in preventing DM1.
Asunto(s)
Chaperonina 60/uso terapéutico , Diabetes Mellitus Tipo 1/prevención & control , Proteínas de Choque Térmico/uso terapéutico , Lactococcus lactis/genética , Fragmentos de Péptidos/uso terapéutico , Proteínas Recombinantes de Fusión/uso terapéutico , Administración Oral , Animales , Chaperonina 60/genética , Citocinas/inmunología , Diabetes Mellitus Tipo 1/epidemiología , Diabetes Mellitus Tipo 1/inmunología , Femenino , Proteínas de Choque Térmico/genética , Humanos , Incidencia , Ratones , Ratones Endogámicos NOD , Fragmentos de Péptidos/genética , Proteínas Recombinantes de Fusión/genética , Linfocitos T/citología , Linfocitos T/inmunologíaRESUMEN
HS061, a new structure analogue of human insulin, was investigated for the treatment of diabetes. In this study, we developed a simple and accurate UPLC-MS/MS method for the pharmacokinetic studies of HS061 in non-diabetic rats followed by a full method validation. Following a simple protein precipitation with acetonitrile, the analyte and internal standard (Levemir, IS) were separated on a Waters XBridge™ BEH300 C4 column (100 mm × 4.6 mm i.d., 3.5 µm) with a gradient elution using acetonitrile and 0.2% aqueous formic acid. The method was operated under pseudo-multiple reaction monitoring (pseudo-MRM) in the positive electrospray ionization mode. The monitored transitions were set at m/z 1563.4â1563.4 for HS061 by pseudo-MRM and m/z 1184.7â454.5 for IS by MRM. Linear calibration curves were obtained over the concentration ranges of 10-1000 ng/mL and no interfering peaks were detected at the retention time of HS061 and IS in blank rat plasma. The mean extraction recoveries of HS061 at three concentrations of 20, 100, 800 ng/mL were greater than 95.17%. Stability was assessed under different conditions and no significant degradations were found. The validated method was then successfully applied in measuring HS061 following subcutaneous (0.5, 1.0, 3.0 U/kg) and intravenous (1.0 U/kg) injection in rat plasma to support the pre-clinical pharmacokinetic study. Maximum plasma concentration (Cmax) and area under the curve (AUC) for the subcutaneous doses of HS061 was approximately dose proportional while other pharmacokinetic parameters showed no significant differences among the three doses (p>0.05). The absolute bioavailability of HS061 after subcutaneous administration at 1.0 U/kg was estimated to be 70.40%.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Insulina/análogos & derivados , Insulina/farmacocinética , Espectrometría de Masas en Tándem/métodos , Animales , Área Bajo la Curva , Estabilidad de Medicamentos , Femenino , Humanos , Insulina/sangre , Insulina/química , Modelos Lineales , Masculino , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
Angiogenesis inhibitors combined with other anticancer drugs have been shown to inhibit tumor growth in animal models and some of them were recently used in clinical trials. In the present study, a whole hepatocellular carcinoma cell lysate based vaccine with diphtheria toxin (DT) and two tandem repeats of microbial HSP70 peptide epitope 407-426 (2 mHSP70407-426, M2) as adjuvant, which was called HDM, was combined with a whole human umbilical vein endothelial cell (HUVEC) vaccine to develop a combination treatment regimen. This combination treatment regimen was named HUVEC-HDM, which was supposed to enhance its antitumor efficiency. HUVEC-HDM was administrated subcutaneously in both prophylactic and therapeutic procedures. Compared to either single vaccine, HUVEC-HDM induced a more significant inhibition on the growth and metastasis of H22 hepatocellular carcinoma in mice and prolonged the survival of tumor-bearing mice. Besides, HUVEC-HDM immunization elicited strong humoral and cellular immune responses targeting tumor cell as well as tumor angiogenesis, which could be responsible for the enhanced antitumor effect. Moreover, histochemistry analysis showed that HUVEC-HDM induced large areas of continuous necrosis within tumors, correlating well with the extent of tumor inhibition. These results not only highlight the superiority of the combined HUVEC-HDM treatment regimen, but also support the translation of such approaches into the clinic for the treatment of patients with hepatocellular carcinoma.
Asunto(s)
Vacunas contra el Cáncer , Carcinoma Hepatocelular/terapia , Células Endoteliales de la Vena Umbilical Humana/trasplante , Neoplasias Hepáticas Experimentales/terapia , Neoplasias Pulmonares/terapia , Animales , Anticuerpos Antineoplásicos/sangre , Carcinoma Hepatocelular/irrigación sanguínea , Carcinoma Hepatocelular/patología , Extractos Celulares/inmunología , Línea Celular Tumoral , Proliferación Celular , Citotoxicidad Inmunológica , Células Endoteliales de la Vena Umbilical Humana/inmunología , Células Endoteliales de la Vena Umbilical Humana/metabolismo , Humanos , Inmunidad Celular , Inmunidad Humoral , Neoplasias Hepáticas Experimentales/irrigación sanguínea , Neoplasias Hepáticas Experimentales/patología , Neoplasias Pulmonares/irrigación sanguínea , Neoplasias Pulmonares/secundario , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Trasplante de Neoplasias , Neovascularización Patológica/prevención & control , Linfocitos T Citotóxicos/fisiologíaRESUMEN
Vaccination with xenogeneic or syngeneic endothelial cells targeting tumor angiogenesis is effective for inhibiting tumor growth. OK432, an effective adjuvant, was mixed with viable human umbilical vein endothelial cells (HUVECs) to prepare a novel HUVECs-OK432 vaccine, which could have an improved therapeutic efficacy. In this study, HUVECs-OK432 was administrated in mice by subcutaneous injection in a therapeutic procedure. The results showed that a stronger HUVEC-specific Abs and cytotoxic T lymphocyte immune response were elicited, which resulted in significant inhibition on the growth of B16F10 melanoma and remarkably prolonged survival of B16F10 melanoma-bearing mice compared with HUVECs. Besides, parallel results were obtained in vitro showing a stronger inhibition of HUVEC proliferation by immune sera of HUVECs-OK432 than that of HUVECs. Moreover, histochemistry and immunohistochemistry analysis showed that HUVECs-OK432 induced large areas of continuous necrosis within tumors and significantly reduced the vessel density, correlating well with the extent of tumor inhibition. Our present results suggest that OK432 could be employed as an effective adjuvant for HUVEC vaccines and therefore should be useful for adjuvant immunotherapy of cancer.
Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Vacunas contra el Cáncer/uso terapéutico , Células Endoteliales de la Vena Umbilical Humana/inmunología , Melanoma Experimental/terapia , Picibanil/uso terapéutico , Linfocitos T Citotóxicos/inmunología , Animales , Ensayo de Inmunoadsorción Enzimática , Humanos , Linfocitos/citología , Linfocitos/inmunología , Masculino , Melanoma Experimental/inmunología , Melanoma Experimental/mortalidad , Ratones , Ratones Endogámicos C57BL , Tasa de Supervivencia , Células Tumorales Cultivadas , VacunaciónRESUMEN
The association between heat shock protein (HSP) 65 and immune diseases has been investigated for many years. The aim of this study was to explore the antitumor effects and possible antitumor mechanism of HSP65. Mice were immunized with HSP65 via subcutaneous injection. Specific IgG antibodies against HSP65 were detected in the sera of immunized mice by enzymelinked immunosorbent assay and verified by western blot analysis. HSP65 effectively inhibited the growth of tumors as well as both the protective and therapeutic antitumor immunities in the melanoma tumor models of mice and prolonged the survival of the tumor-bearing mice. Furthermore, HSP65 also attenuated tumor-induced angiogenesis in the intradermal model and pulmonary metastasis in the tail intravenously injected model of mice. It was demonstrated that the administration of HSP65 is able to effectively inhibit the growth, angiogenesis and metastasis of murine melanoma in vivo and provide new prospects for the immunotherapy of melanoma.
Asunto(s)
Vacunas contra el Cáncer/administración & dosificación , Proteínas de Choque Térmico/administración & dosificación , Melanoma Experimental/patología , Melanoma Experimental/terapia , Animales , Anticuerpos/inmunología , Especificidad de Anticuerpos/inmunología , Vacunas contra el Cáncer/inmunología , Línea Celular Tumoral , Proteínas de Choque Térmico/inmunología , Inmunoglobulina G/inmunología , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/secundario , Masculino , Ratones , Neovascularización Patológica/inmunología , Neovascularización Patológica/terapia , Carga Tumoral/inmunologíaRESUMEN
To construct, express and purify Exendin-4 analogue and detect its biological activity in vivo. Insert gene sequence into fusion partner ofpED plasmid which is helped to purification, entitled the new recombinant plasmid 5 Exendin-4 analogue polypeptide gene and fusion partner gene was linked by acid hydrolysisgene, transformed to E. coli BL21 and the fusion protein was induced by lactose. After acid hydrolysis, the Exendin-4 analogue polypeptide separated from fusion chaperon. Anion charge chromatography were used to further purification. 6 to 8 week-old ICR mice were injected (s.c) with Exendin-4 analogue, blood glucose and plasma insulin level was detected in different period after oral glucose tolerance test. The results show that high expression of inclusion body was induced by lactose, which accounted for 40% of germ proteins, the Exendin-4 analogue was obtained with the purity of 91.8% after being purified by anion charge chromatography. Bioactivity assay showed that the level of blood glucose of mouse which treated with exendin-4 analogue was obviously decreased to normal (P < 0.01), and the level of plasma insulin was increased obviously (P < 0.01).